What AMP CMD Partners Are Saying

Amgen

Amgen is committed to advancing cardiometabolic research to help patients living with serious disease. We are proud to participate in the Accelerating Medicines Partnership to help further research progress in this field through collaboration with leading industry and non-profit partners. The ability to leverage each partners’ insights and experience, along with integrating the power of human data, will help to identify and validate novel pathways and potential therapeutic targets to address unmet clinical needs in patients with metabolic disorders such as heart failure, obesity and diabetes.”

Narimon Honarpour, Ph.D.
Vice President of Translational Medicine
Amgen


Eli Lilly and Company

Diabetes and obesity are complex conditions that often lead to complications and poor long-term outcomes. Our vision is to address these conditions and the complications associated with them – such as cardiovascular disease, heart failure, chronic kidney disease, and NASH – by developing innovative medicines that lead to better outcomes and more productive lives.”

Ruth Gimeno, Ph.D.
Vice President, Diabetes Research and Clinical Investigation
Eli Lilly and Company


Novo Nordisk

We are excited to work on this important collaboration designed to decode the complexities of common metabolic disorders that will lead to an increased understanding of the disease drivers. This public-private partnership calls for a critical mass of researchers determined to research diabetes, obesity, non-alcoholic steatohepatitis, chronic kidney and cardiovascular diseases, with the aim to expand research strengths to address the significant unmet need for patients living with these diseases.”

Karin Conde-Knape, Ph.D.
Senior Vice President for Global Drug Discovery
Novo Nordisk


Pfizer Inc.

Pfizer is proud to collaborate with our partners in the AMP CMD to advance the critical field of cardiometabolic research. With the opportunity to help billions of people worldwide, a comprehensive, collaborative, patient-centric approach is essential. We believe this partnership will help researchers better understand the biological factors linking these serious conditions – ultimately furthering the development of potential therapies to improve patients’ lives.”

Morris Birnbaum, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit
Pfizer Inc.